Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sapanisertib + everolimus
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sapanisertib + everolimus is a **combination regimen** of two oral small molecule inhibitors targeting the mTOR (mechanistic target of rapamycin) pathway. **Sapanisertib** is a dual mTORC1/mTORC2 inhibitor, designed to more completely inhibit the PI3K/AKT/mTOR oncogenic signaling cascade than first-generation mTOR inhibitors, which only inhibit mTORC1. **Everolimus** is a selective mTORC1 inhibitor, approved for various cancers including renal cell carcinoma and breast cancer. This combination has been explored in clinical trials for enhanced pathway suppression to overcome resistance mechanisms in advanced or metastatic cancers, particularly clear cell renal cell carcinoma.
02
Targets
Mechanistic target of rapamycin kinase complex 2Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on sapanisertib + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sapanisertib + everolimus.